Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”) THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a Virtual ...

Core Insights - Autonomix Medical, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, NY [1] - The company focuses on innovative technologies for diagnosing and treating diseases of the nervous system, with a first-in-class platform technology that includes a catheter-based microchip sensing array [4][5] - The initial application of this technology is aimed at treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [5] Company Overview - Autonomix Medical, Inc. specializes in medical devices that aim to revolutionize the diagnosis and treatment of nervous system diseases [4] - The company's technology is designed to detect and differentiate neural signals with greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4] - The investigational technology has not yet received marketing clearance in the United States [5] Conference Participation - Management will be available for in-person one-on-one meetings with qualified investors registered for the conference [2] - A video webcast of the presentation will be available on-demand starting September 8, 2025, at 7:00 AM ET, and will be archived for 90 days [3]

Core Insights - Autonomix Medical, Inc. is advancing precision nerve-targeted treatments and has announced a follow-on market expansion study phase ("PoC 2") for its proof-of-concept trial [1] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - This technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [3] Technology Development - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which causes severe pain and lacks reliable treatment options [4] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management across a wide disease spectrum [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4]

Core Insights - Autonomix Medical, Inc. has successfully completed the initial phase of its first-in-human proof-of-concept trial ("PoC 1") demonstrating clinically meaningful pain reduction in patients with pancreatic cancer pain [1][2] - The company plans to initiate a market expansion study ("PoC 2") targeting additional visceral cancers and earlier stage pancreatic cancer, expected to commence in Q2 2025 [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases involving the nervous system [3] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - The initial development of this technology is aimed at treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [4] Future Prospects - The technology has the potential to address a wide range of indications beyond pancreatic cancer, including cardiology, hypertension, and chronic pain management [4] - The investigational technology has not yet received marketing clearance in the United States [4]